文献速递心血管MR

酶替代治疗对法布里病心脏MRI表现的影响:系统综述与荟萃分析

Effects of Enzyme Replacement Therapy on Cardiac MRI Findings in Fabry Disease: A Systematic Review and Meta-Analysis.
PubMed 文献 · Radiol Cardiothorac Imaging · 2024-01-01

该系统综述与荟萃分析纳入11项研究共445例法布里病患者,评估酶替代治疗前后心脏MRI参数变化。结果显示左心室质量、最大左心室壁厚度和T1 mapping值趋于稳定,而晚期钆增强范围轻度增加。

要点

  • 酶替代治疗前后T1 mapping值无显著变化(均差6毫秒,95%CI:-2,15)。
  • 左心室质量指数无显著变化(均差-1 g/m²,95%CI:-6,3)。
  • 晚期钆增强范围轻度增加(均差1%,95%CI:1,1)。

核心结论

  • 在法布里病患者中,酶替代治疗与左心室质量、最大左心室壁厚度和T1 mapping值的稳定相关,而晚期钆增强范围轻度增加。

研究设计与样本

  • 系统综述与荟萃分析,检索2000年1月1日至2024年1月1日PubMed、ClinicalTrials.gov、Embase和Cochrane Library数据库,最终纳入11项研究共445例法布里病患者(平均年龄41岁±11;277例男性,168例女性),采用随机效应模型汇总基线与随访参数的均差,研究方案注册于PROSPERO(CRD42022336223)。

诊断标准与关键数值

  • T1 mapping均差6毫秒(95%CI:-2,15;2项研究,70例患者,I²=88%),无显著变化。
  • 左心室质量指数均差-1 g/m²(95%CI:-6,3;4项研究,290例患者,I²=81%),无显著变化。
  • 左心室质量均差-18 g(95%CI:-33,-3;7项研究,107例患者,I²=96%),轻度降低。
  • 最大左心室壁厚度均差-1 mm(95%CI:-2,-0.02;6项研究,151例患者,I²=90%),轻度降低。
  • 晚期钆增强范围均差1%(95%CI:1,1;3项研究,114例患者,I²=85%),轻度增加。

局限性

  • T1 mapping分析异质性I²=88%。
  • 左心室质量指数分析异质性I²=81%。
  • 左心室质量分析异质性I²=96%。
  • 最大左心室壁厚度分析异质性I²=90%。
  • 晚期钆增强范围分析异质性I²=85%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To perform a systematic review and meta-analysis to assess the effect of enzyme replacement therapy on cardiac MRI parameters in patients with Fabry disease. Materials and Methods A systematic literature search was conducted from January 1, 2000, through January 1, 2024, in PubMed, ClinicalTrials.gov, Embase, and Cochrane Library databases. Study outcomes were changes in the following parameters: (a) left ventricular wall mass (LVM), measured in grams; (b) LVM indexed to body mass index, measured in grams per meters squared; (c) maximum left ventricular wall thickness (MLVWT), measured in millimeters; (d) late gadolinium enhancement (LGE) extent, measured in percentage of LVM; and (e) native T1 mapping, measured in milliseconds. A random-effects meta-analysis of the pooled mean differences between baseline and follow-up parameters was conducted. The study protocol was registered in PROSPERO (CRD42022336223). Results The final analysis included 11 studies of a total of 445 patients with Fabry disease (mean age ± SD, 41 years ± 11; 277 male, 168 female). Between baseline and follow-up cardiac MRI, the following did not change: T1 mapping (mean difference, 6 msec [95% CI: -2, 15]; two studies, 70 patients, I2 = 88%) and LVM indexed (mean difference, -1 g/m2 [95% CI: -6, 3]; four studies, 290 patients, I2 = 81%). The following measures minimally decreased: LVM (mean difference, -18 g [95% CI: -33, -3]; seven studies, 107 patients, I2 = 96%) and MLVWT (mean difference, -1 mm [95% CI: -2, -0.02]; six studies, 151 patients, I2 = 90%). LGE extent increased (mean difference, 1% [95% CI: 1, 1]; three studies, 114 patients, I2 = 85%). Conclusion In patients with Fabry disease, enzyme replacement therapy was associated with stabilization of LVM, MLVWT, and T1 mapping values, whereas LGE extent mildly increased. Keywords: Fabry Disease, Enzyme Replacement Therapy (ERT), Cardiac MRI, Late Gadolinium Enhancement (LGE) Supplemental material is available for this article. © RSNA, 2024.

来源:Radiol Cardiothorac Imaging,查看原文。版权归原作者所有。

引用

  1. Figliozzi S, Kollia E, Simistiras A, et al. Effects of Enzyme Replacement Therapy on Cardiac MRI Findings in Fabry Disease: A Systematic Review and Meta-Analysis. Radiol Cardiothorac Imaging. 2024. PMID: 38842453. doi:10.1148/ryct.230154

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。